Multiple Myeloma Coverage from Every Angle

Shaji K. Kumar, MD, on Clinical Implications of Changing Treatment Paradigms for Multiple Myeloma

Posted: Monday, November 22, 2021

Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, offers clinical pearls on adding a fourth drug to the induction regimen for patients with newly diagnosed multiple myeloma, the new drug classes that could improve outcomes, and how to decide whether and when to alter treatments.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.